Jubilant Pharmova Q1 Results: Net profit at ₹6.4 crore; Revenue rises 9% YoY | Mint
Active Stocks
Wed Feb 28 2024 15:59:21
  1. Tata Motors share price
  2. 957.75 -0.52%
  1. Tata Steel share price
  2. 140.75 -2.36%
  1. HDFC Bank share price
  2. 1,408.15 -0.87%
  1. Power Grid Corporation Of India share price
  2. 279.55 -4.43%
  1. ITC share price
  2. 408.60 -0.62%
Business News/ Markets / Stock Markets/  Jubilant Pharmova Q1 Results: Net profit at 6.4 crore; Revenue rises 9% YoY

Jubilant Pharmova Q1 Results: Net profit at ₹6.4 crore; Revenue rises 9% YoY

Jubilant Pharmova Ltd's Q1 net profit falls 86.4% YoY to ₹6.4 crore, down from ₹47.1 crore in the same period last year. Shares down over 2%.

Jubilant Pharmova shares were trading at ₹388.50, down over 2%. (AP)Premium
Jubilant Pharmova shares were trading at 388.50, down over 2%. (AP)

Pharmaceutical company, Jubilant Pharmova Ltd on Wednesday reported an 86.4% year-on-year fall in its consolidated net profit (attributable to owners of the company) for the fiscal's first quarter ended June (Q1FY24) to 6.4 crore. The company had reported a profit of 47.1 crore in the year-ago period. The company in Q4FY23 posted a net loss of 97.9 crore. 

For the quarter ended June 30 (Q1FY24), consolidated revenue jumped 9.3% year-on-year to 1,587 crore from 1,451.7 crore in Q1FY23. The company's consolidated income from operations rose 8.7% on year to 1,566.5 crore from 1,440.5 crore.

Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) also came in at 178 crore in the quarter under review, up by nearly 30% from 137 crore in Q1FY23. Similarly, EBITDA margins rose to 11.2% in Q1 FY24, as against 9.9% in the same quarter last year.

In the quarter, total expenses stood at 1,568.9 crore versus 1,393.8 crore in Q1FY23 and 1,785.6 crore in Q4FY23.

On the technical front, Jubilant Pharmova shares were trading in red on Wednesday's session. 

According to Rajesh Bhosale - Equity Technical and Derivative Analyst, Angel One,yesterday's prices showed some positive traction however today post the result prices are seeing some weakness along with increase in volume activity.

 The recent trend for the stock had been positive however we now sense that there's some profit booking that may continue in the near term towards 370 - 365 levels. On the flip side yesterday's high around 410 is considered as immediate resistance, only beyond wihich the primary uptrend may resume.

As per trendlyne data, the stock price rose 3.5% and underperformed its sector by 15.1% in the past year.

Jubilant Pharmova Q4 results: Consolidated net loss widens sequentially to 98 crore; to pay 5 per share dividend

Disclaimer: The promoters of HT Media Ltd, which publishes Mint, and Jubilant Group are closely related. There are, however, no promoter cross-holdings.



Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
More Less
Published: 19 Jul 2023, 02:19 PM IST
Next Story footLogo
Recommended For You

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App